Want to see SE:CANTA full AI Analyst Report?
CANTA Stock Chart & Stats
kr4.07
-kr0.02(-1.25%)
At close: 4:00 PM EST
kr4.07
-kr0.02(-1.25%)
Day’s Range― - ―
52-Week Rangekr1.80 - kr6.59
Previous CloseN/A
Volume611.88K
Average Volume (3M)1.42M
Market Cap
kr518.78M
Enterprise Valuekr288.48M
Total Cash (Recent Filing)kr258.03M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)2.8
Beta0.84
Next Earnings
Aug 19, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.65
Shares Outstanding281,944,980
10 Day Avg. Volume1,074,033
30 Day Avg. Volume1,417,172
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)3.91
Price to Sales (P/S)3.28
P/FCF Ratio6.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr14.00Price Target Upside243.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Operating And Free Cash FlowThe company generated substantial operating cash flow (158.1m) and nearly identical free cash flow (157.6m) in the latest TTM, indicating strong cash conversion and earnings quality. Durable FCF supports ongoing R&D, partner programs and reduces near-term external financing needs if repeatable.
Zero Debt / Conservative Balance SheetA zero-debt balance sheet materially lowers financial risk and interest burden, preserving flexibility to fund clinical development via partnerships or selective financings. This structural strength improves solvency and gives management runway to pursue strategic options over the medium term.
High Margins In Latest PeriodThe roughly 51% net and EBIT margins in the latest TTM demonstrate the company's ability to generate high-margin income when development or licensing milestones occur. Such margin potential, if diversified across programs or partners, can sustainably fund R&D and corporate costs.
Bears Say
Episodic Revenue And Volatile ResultsHistoric multi-year stretches of zero revenue and losses indicate the company’s income profile is event-driven (milestones/licensing) rather than recurring. That episodic nature creates forecasting uncertainty and risks interruptions in cash generation absent new milestone events or structural revenue streams.
Declining Equity And Dilution RiskThe decline in shareholders' equity versus prior years reflects past losses and/or capital raises, flagging dilution risk. As a clinical-stage biotech historically reliant on financing, decreased equity cushions imply a higher likelihood of future equity issuance to fund development, impacting long-term shareholder value.
Business Model Relies On External Financing/partnersRevenue and cash generation depend heavily on collaborations, licensing milestones, grants and equity raises rather than product sales. This structural dependence ties financial health to successful deals and capital markets access, increasing vulnerability if partnerships or financing windows tighten.
Cantargia AB News
CANTA FAQ
What was Cantargia AB’s price range in the past 12 months?
Cantargia AB lowest stock price was kr1.80 and its highest was kr6.59 in the past 12 months.
What is Cantargia AB’s market cap?
Cantargia AB’s market cap is kr518.78M.
When is Cantargia AB’s upcoming earnings report date?
Cantargia AB’s upcoming earnings report date is Aug 19, 2026 which is in 25 days.
How were Cantargia AB’s earnings last quarter?
Cantargia AB released its earnings results on May 19, 2026. The company reported -kr0.13 earnings per share for the quarter, beating the consensus estimate of -kr0.18 by kr0.05.
Is Cantargia AB overvalued?
According to Wall Street analysts Cantargia AB’s price is currently Undervalued.
Does Cantargia AB pay dividends?
Cantargia AB does not currently pay dividends.
What is Cantargia AB’s EPS estimate?
Cantargia AB’s EPS estimate is -0.17.
How many shares outstanding does Cantargia AB have?
Cantargia AB has 281,944,980 shares outstanding.
What happened to Cantargia AB’s price movement after its last earnings report?
Cantargia AB reported an EPS of -kr0.13 in its last earnings report, beating expectations of -kr0.18. Following the earnings report the stock price went down -1.18%.
Which hedge fund is a major shareholder of Cantargia AB?
Currently, no hedge funds are holding shares in SE:CANTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cantargia AB
Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to target Interleukin-1 Receptor Accessory Protein (IL1RAP). This innovative treatment aims to identify and stimulate the immune system to destroy cancer cells, while also mitigating tumor-related inflammation fueled by the Interleukin-1 system, and is currently in Phase IIa clinical trials. The company is also advancing CAN10, another IL1RAP-specific antibody, through preclinical development for autoimmune and inflammatory conditions like systemic sclerosis and myocarditis. Additionally, Cantargia is exploring other CANxx antibodies that also interact with IL1RAP. The manufacturing and production of CAN04 are facilitated through partnerships with Patheon Biologics BV and BioWa Inc., and its clinical study is supported by Specialized Medical Services-oncology BV.
CANTA Stock 12 Month Forecast
Average Price Target
kr14.00
▲(243.98% Upside)
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
―
Guard Therapeutics International AB
―
Immunicum AB
―